Vitamin D therapy in chronic kidney disease and end stage renal disease - PubMed (original) (raw)

Review

Vitamin D therapy in chronic kidney disease and end stage renal disease

Michal L Melamed et al. Clin J Am Soc Nephrol. 2012 Feb.

Abstract

Vitamin D has garnered much research and debate about supplementation in recent years, not only as it pertains to patients with kidney disease but also to those in the general population. This review discusses observational and available clinical trial evidence about the effects of both calcitriol and vitamin D analogs (active) and ergocalciferol and cholecalciferol (nutritional) vitamin D in patients with CKD and ESRD.

PubMed Disclaimer

Figures

Figure 1.

Physiology of vitamin D in the body. It circulates as 25-hydroxyvitamin D (25D), which then gets converted in the kidney to 1,25-dihydroxyvitamin D (1,25D). The 1,25D has endocrine effects, shown at the right. 25D can also be taken up by monocytes and other cells where it is converted to 1,25D acting in an autocrine fashion to upregulate cathelicidin production.

Cited by

Association of Vitamin D Deficiency and Insufficiency with Pathology in Hospitalized Patients.
Bucurica S, Prodan I, Pavalean M, Taubner C, Bucurica A, Socol C, Calin R, Ionita-Radu F, Jinga M. Bucurica S, et al. Diagnostics (Basel). 2023 Mar 6;13(5):998. doi: 10.3390/diagnostics13050998. Diagnostics (Basel). 2023. PMID: 36900141 Free PMC article.
25-OH vitamin D threshold for optimal bone mineral density in elderly patients with chronic kidney disease.
Roy D, Ng CY, Kog ZX, Yeon W, Poh CB, Koduri S, Chionh CY, Sultana R, Hai Kiat Puar T. Roy D, et al. Front Aging. 2022 Oct 21;3:1026663. doi: 10.3389/fragi.2022.1026663. eCollection 2022. Front Aging. 2022. PMID: 36338833 Free PMC article.
Severe 25-Hydroxyvitamin D Deficiency May Predict Poor Renal Outcomes in Patients With Biopsy-Proven Diabetic Nephropathy.
Zhou T, Shen L, Li Z, Jia J, Xing H, Wang N, Jiao Q, Fan Y. Zhou T, et al. Front Endocrinol (Lausanne). 2022 May 4;13:871571. doi: 10.3389/fendo.2022.871571. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600603 Free PMC article.
Associations Between 25-Hydroxyvitamin D, Kidney Function, and Insulin Resistance Among Adults in the United States of America.
Geng J, Qiu Y, Li Y, Li J, Liao R, Du H, Jiang L, Wang L, Qin Z, Yang Q, Yu Q, Zhang Z, Su B. Geng J, et al. Front Nutr. 2022 Feb 15;8:716878. doi: 10.3389/fnut.2021.716878. eCollection 2021. Front Nutr. 2022. PMID: 35242790 Free PMC article.
Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease.
Sagar PS, Saravanabavan S, Munt A, Wong ATY, Rangan GK. Sagar PS, et al. J Cardiovasc Dev Dis. 2021 Oct 29;8(11):144. doi: 10.3390/jcdd8110144. J Cardiovasc Dev Dis. 2021. PMID: 34821697 Free PMC article.

References

1. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34: 368–375, 1988 - PubMed
1. Weisman Y, Vargas A, Duckett G, Reiter E, Root AW: Synthesis of 1,25-dihydroxyvitamin D in the nephrectomized pregnant rat. Endocrinology 103: 1992–1996, 1978 - PubMed
1. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E: Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 298: F1315–F1322, 2010 - PMC - PubMed
1. Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1,25-dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175: 768–769, 1972 - PubMed
1. Brumbaugh PF, Haussler MR: 1 Alpha,25-dihydroxycholecalciferol receptors in intestine. I. Association of 1 alpha,25-dihydroxycholecalciferol with intestinal mucosa chromatin. J Biol Chem 249: 1251–1257, 1974 - PubMed

Vitamin D therapy in chronic kidney disease and end stage renal disease - PubMed (original) (raw)